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Aim To evaluate how coronary computed tomography-
angiography (CCTA) altered the management and treat-
ment of patients with suspected coronary artery disease 
(CAD).
Methods During 2009, we studied 792 consecutive pa-
tients with suspected CAD. CCTA was performed in all pa-
tients using a 64-slice dual-source CT scanner and stan-
dard scanning protocols.
Results After CCTA, obstructive CAD was excluded in 666 
patients. During the 12-month clinical follow-up, 98.6% of 
these patients were free of major adverse cardiac events. 
Also, the indication for cardiac catheterization (CC) was re-
voked in 77.2% of patients. It was also revoked in all pa-
tients with low Morise pre-test risk, 80.7% with interme-
diate risk, and 72.6% with high risk. Medical therapy was 
changed in 54.7% of patients with confirmed CAD.
Conclusion CCTA can reliably exclude significant CAD not 
only in patients with low and moderate risk, but also in 
those with high risk. It can also reliably replace CC in the 
majority of elective patients regardless of risk stratification. 
It can also be useful in risk reclassification and optimization 
of medical therapy in patients with CAD.
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Coronary artery disease (CAD) is the leading cause of death 
in most developed countries (1-3). In 50%-60% of cases, 
the disease is only diagnosed when the patient experi-
ences heart attack or sudden death (2). Early detection of 
CAD is extremely important, so the new diagnostic meth-
ods are constantly evolving. Coronary computed tomog-
raphy-angiography (CCTA) is a new, noninvasive imaging 
method for coronary arteries (4). It allows direct imaging of 
coronary artery walls and analysis of atherosclerotic plaque 
(5,6). Therefore, it is a useful method not only for exclud-
ing CAD, but also for the selection of optimal drug therapy 
(7). With current generation 64-slice scanners, CCTA can be 
performed in most patients with minimal patient discom-
fort and high diagnostic accuracy (7).
Although invasive angiography is still considered the gold 
standard for the diagnosis of coronary artery disease, CCTA 
is now recommended as a method of choice for ruling out 
significant CAD in patients with stable and unstable angi-
nal syndromes with low to moderate likelihood of CAD (8). 
CCTA may be especially useful in patients with borderline 
symptoms or equivocal noninvasive testing (7).
As a transitional European country, our country until re-
cently had a substantial lack of invasive cardiologists and 
equipment.  Consequently,  the  waiting  lists  for  cardiac 
catheterization (CC) were quite long. Patients on the wait-
ing lists in whom stress-test could not be performed or 
with unequivocal findings on stress-test, as well as patients 
disinclined to undergo invasive CC, were forwarded to our 
institution for CCTA. The vast majority of patients were re-
ferred by cardiologists outside our institution.
In the outpatient setting, where CCTA has been used for 
the evaluation of patients with stable chest pain symp-
toms, no studies have directly measured the impact of 
CCTA on clinical decision-making or on patient outcomes. 
For these reasons, during 2009 we conducted a prospec-
tive study of clinical impact of CCTA on the management 
and treatment of patients with suspected CAD. The aim of 
this study was to evaluate if CCTA changed the manage-
ment and treatment in some of these patients.
MateriaLs anD MetHoDs
Patient selection
The study included all patients undergoing CCTA in our in-
stitution during 2009. Signed informed consent was ob-
tained from all patients before the investigation. Patients 
were eligible for the study if CAD was suspected but not 
previously  diagnosed.  A  structured  interview  was  per-
formed before the investigation, and information about 
age, height, and weight of the patient, cardiac history, and 
current medication was collected. The following cardiac 
risk factors were recorded:
1. presence and degree of hypertension (for binary analy-
sis, a systolic blood pressure >140 mm Hg was considered 
as abnormal regardless of antihypertensive therapy);
2. diabetes mellitus (defined as fastening blood glucose 
level >7 mmol/L or use of oral antidiabetic therapy or in-
sulin);
3. smoking (defined as current smoker or previous smoker 
within the last year);
4. positive family history (defined as presence of CAD: myo-
cardial infarction, coronary bypass or angioplasty, or sud-
den death in first-degree relatives <55 years of age if male 
and <65 years of age if female).
In addition, laboratory tests for total cholesterol, low-den-
sity  lipoprotein,  and  high-density  lipoprotein  fractions, 
and triglycerides were performed. Finally, two prognostic 
scores were calculated: the Morise pre-test score and the 
Framingham  risk  score  with  the  established  categorical 
model using low-density lipoprotein cholesterol accord-
ing to Wilson et al (9,10).
Both Morise and the Framingham pre-test risk scores were 
calculated on the basis of patients’ age, symptoms (typical 
angina, atypical angina, and non-anginal chest pain), medi-
cation usage, and other coronary risk factors. Risk factors in-
clude the following: current or prior cigarette smoking, his-
tory of hypertension (or antihypertensive therapy), history 
of insulin- or noninsulin-requiring diabetes, history of high 
cholesterol or taking cholesterol-lowering therapy, a family 
history of premature (before 60 years) coronary disease (in-
farction, coronary bypass or angioplasty, sudden death) in 
the first degree relatives, and obesity defined as a body mass 
index (kg/m2)>27. Based on Morise pre-test score, patients 
in the study were classified into 3 groups – with low, inter-
mediate, and high risk (9). The study design was approved 
by the ethics committee of Sunce Clinic, Zagreb, Croatia.
Ct procedure
All patients were scanned on a 64-slice dual-source CT 
scanner (Somatom Definition, Siemens Medical So-HEART DISEASES 6 Croat Med J. 2012;53:4-10
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lutions, Forchheim, Germany). The detailed CT scan proto-
col was followed as described elsewhere (11,12). Scanning 
parameters  were  detector  collimation  2 × 32 × 0.6  mm3, 
slice collimation 2 × 64 × 0.6 mm3 by means of a z-flying 
focal spot, gantry rotation time 330 ms, and pitch of 0.2-
0.5 depending on the heart rate. For reduction of radiation 
dose exposure, an electrocardiographically gated modula-
tion of the tube current was used in patients with stable 
sinus rhythm. Images were reconstructed in the mid-di-
astole with individually optimized position of the recon-
struction window. Additional image reconstructions were 
performed in the end-systole if required. A data set of axial 
slices, multiplanar reformations, and thin-slab maximum 
intensity projections (5-mm thickness, 1-mm increment) 
was used for the analysis.
To lower the heart rate, up to 4 doses of 5 mg metoprolol 
were administered intravenously to patients with the heart 
rate ≤60 beats/min. All patients with a systolic blood pres-
sure of at least 100 mm Hg received nitroglycerin 0.8 mg 
sublingually for coronary vasodilatation. Images for calcium 
scoring were not acquired routinely. Contrast timing was 
tested by an initial bolus-timing scan using 20 mL of con-
trast (Iopamiro 370, Bracco S.p.a, Milan, Italy), iodine con-
tent 370 mg/mL, followed by a 50 mL saline chaser. The 
contrast-enhanced scan was obtained using 80 to 140 mL 
of contrast individually adapted to the selected table feed 
and scan range at a rate of 4 to 5 mL/s followed by a 50 mL 
saline chaser. The coronary artery tree was segmented ac-
cording to the modified American Heart Association clas-
sification (13). Each segment with a diameter ≥1.5 mm was 
evaluated visually by a single experienced reader for the de-
gree of luminal narrowings, and rated semiquantitatively in 
4 groups: <25%, 25%-49%, 50%-74%, and ≥75%. Obstruc-
tive coronary artery disease was defined as stenosis of 50% 
or more of the diameter of the left main coronary artery or 
stenosis of 75% or more of the diameter of a major epicardi-
al or branch vessel that was more than 2.0 mm in diameter. 
Patients with no coronary artery disease and non-obstruc-
tive coronary artery disease were also identified.
Findings and follow-up
The following parameters were analyzed:
1. Proportion of patients with no CAD, non-obstructive 
CAD, or obstructive CAD on CCTA.
2. Proportion of patients in whom an earlier indication 
for CC was revoked after CCTA.
3. Proportion of patients in whom CCTA led to the change 
in  medical  therapy.  Optimal  medical  therapy  for  CAD 
(OMT) was defined according to the Clinical Outcomes 
Utilizing  Revascularization  and  Aggressive  Drug  Evalua-
tion (COURAGE) trial (14). OMT included antiplatelet ther-
apy with aspirin (81-325 mg/d) or clopidogrel (75 mg/d) 
if aspirin intolerant. It also included lipid-lowering therapy 
to a target low-density lipoprotein of 2.5-3 mmol/L. Anti-
ischemic  therapy  included  beta  blocator,  antagonist  of 
calcium channels, and isosorbide mononitrate, alone or in 
combination. Any medical therapy (AMT) for CAD was de-
fined as incomplete or insufficiently aggressive in compari-
son to OMT. OMT was introduced in all patients with CAD 
on CCTA, where it was not previously present. Therapy up-
grade was, accordingly, defined as an introduction of one 
or more new agents to achieve OMT. Change in the dose 
of already existing agent was not considered here. In pa-
tients in whom CAD was excluded on the basis of CCTA, 
any specific therapy for CAD was ruled out, unless it was 
introduced for some other reason (confirmed atheroscle-
rosis elsewhere, hypertension, etc). Therapy reduction was, 
accordingly, defined as exclusion of one or more agents in 
patients who have been taking these medications for sus-
pected CAD, and after CAD was not confirmed on CCTA.
4.  Proportion  of  patients  who  were  referred  for  cardiac 
revascularization  after  obstructive  CAD  was  found  on 
CCTA, and who received revascularization.
Twelve-month clinical follow-up period was established 
for two groups of patients:
a) patients with no CAD on CCTA,
b) patients with non-obstructive CAD on CCTA.
Follow-up  information  was  obtained  by  direct  or  tele-
phone contact. All reported events were verified by hospi-
tal records or direct contacts with the attending physician. 
The following clinical events were recorded in the follow-
up period:
1. cardiac death;
2. nonfatal myocardial infarction;
3. unstable angina pectoris requiring hospitalization;
4. coronary revascularization not indicated on CCTA (either 
by bypass surgery or percutaneous coronary intervention).7 Jukić et al: Influence of coronary CT-angiography on patient management
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All patients with obstructive CAD on CCTA were sent to 
revascularization. For all of them revascularization was or-
ganized within 4 weeks after the CCTA, and all had a con-
trol CC before revascularization. Due to the briefness of this 
period, and since their further management was organized 
outside of our institution, these patients were not includ-
ed in the further study. Patients with obstructive CAD on 
CCTA, which was not confirmed at CC, were also not in-
cluded in further study because their further management 
was performed outside of our institution.
statistical analysis
χ2 test was used to establish the relationships between 
pairs  of  categorical  variables. Two-tailed  test  for  differ-
ences between proportions was used for comparison be-
tween  simple  percentages.  Statistical  significance  level 
was set at 0.05.
resuLts
study population and follow-up
From January 1, 2009 to December 31, 2009, CCTA was 
performed in 1176 patients, 264 of whom had previously 
known CAD, 135 underwent a previous bypass surgery, 
and 129 had implanted coronary stents. Sixty-three pa-
tients were scanned due to the large blood vessels and/
or  valvular  disease. These  327  patients  were  excluded 
from the study. In total, the study included 849 patients. 
In 57 patients, one or more major coronary arteries were 
not fully available to analysis due to the technical prob-
lems and artifacts. Further management was performed 
elsewhere, and these patients were not included in fur-
ther analysis. There were 792 patients available for further 
study.
Patients’ characteristics
Patients’ characteristics and coronary risk factor profile in-
dicate a study population of intermediate to high risk for 
CAD (Table 1). The majority of patients had moderate risk 
(423 of 792, 53.4%), followed by those with high (270 of 
792, 34.1%), and low risk (99 of 792, 12.5%). Of 513 pa-
tients previously scheduled for CC, 252 (49.1%) had high 
risk, 249 (48.5%) intermediate risk, and 12 (2.3%) low risk. 
The largest proportion of patients with AMT for CAD had 
high risk (246 of 270, 91.1%), followed by those with in-
termediate risk (369 of 423, 87.2%), and low risk (66 of 99, 
66.7%).
incidence of CaD
Altogether 276 of 792 (34.8%) patients had no CAD on 
CCTA, 390 (49.2%) patients had non-obstructive CAD, and 
126 (15.9%) patients had obstructive CAD. The majority of 
patients with no CAD had low risk (45 of 99, 45.5%), the 
majority of patients with non-obstructive CAD had inter-
mediate risk (213 of 423, 50.3%), and the majority of pa-
tients with obstructive CAD had high risk (69 of 270, 25.5%). 
The correlation of CAD findings and risk stratification was 
significant (P < 0.001, χ2 test). However, high risk was not a 
sufficient predictor of obstructive CAD, because only 26% 
of patients with high risk actually had obstructive CAD on 
CCTA.
indication for elective CC revoked after CCta
On CCTA, CAD was excluded in 159 of 513 patients sched-
uled for elective CC (30.1%), 237 (46.2%) patients had non-
obstructive CAD, and 117 (22.8%) had obstructive CAD. 
Based on these results, indication of CC was revoked in all 
patients with no CAD and non-obstructive CAD, which is 
altogether 396 of 513 (71.9%) patients. It was also revoked 
in all 12 patients with low risk, in 201 of 249 (80.7%) pa-
tients with intermediate risk, and 183 of 252 (72.6%) pa-
tients  with  high  risk. The  difference  between  high  and 
intermediate risk group was significant (P < 0.05). The sig-
nificance for low risk group could not be calculated be-
cause of the small patient number.
taBLe 1. Characteristics of patients with suspected coronary 
artery disease
Clinical characteristics, median (range) n = 792
age, years   61.3 (31.4-86.5)
Male, n (%) 334 (42)
Body mass index (kg/m2)   27.2 (23.1-29.2)
Hypertension, n (%) 490 (63)
smoking, n (%) 309 (39)
Diabetes mellitus, n (%) 135 (17)
Chest pain, n (%)
typical 261 (33)
atypical 530 (67)
Positive test for ischemia, n (%)   66 (25)
systolic blood pressure (mmHg) 145 (105-180)
Diastolic blood pressure (mmHg)   89 (60-110)
Cholesterol level (mmol/L)     6.4 (4.1-8.9)
Low density lipoprotein cholesterol (mmol/l)     4.1 (2.0-5.1)
High density lipoprotein cholesterol (mmol/L)     0.9 (0.6-1.5)
triglycerides (mmol/L)     2.9 (0.9-7.11)
Framingham risk score (10)   13 (1-33)
Morise pre-test score (9)   13 (6-20)HEART DISEASES 8 Croat Med J. 2012;53:4-10
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Changes in medical therapy after CCta
In 495 of 792 patients (62.5%), there were no changes in 
medical therapy for CAD after CCTA. Therapy was modified 
in 297 patients (37.5%) – increased in 282 patients (35.6%) 
and reduced in 15 patients (1.9%).
Proportionally, therapy was increased most often in pa-
tients with high risk (156 of 270, 57.7%), followed by pa-
tients with low risk (27 of 99, 27.3%) and patients with in-
termediate risk (84 of 423, 19.9%). The differences between 
high risk group and low risk group and intermediate risk 
group, respectively, were significant (P < 0.05). The differ-
ence between low risk group and intermediate risk group 
was not significant (P > 0.05). Proportionally, therapy was 
most often reduced in patients with low risk (3 of 9, 33%), 
and not as often in patients with intermediate risk (12 out 
of 423, 2.8%). There were no high risk patients in whom 
therapy was reduced. The differences between the three 
risk groups in this respect were not significant (P > 0.05).
Patients referred for cardiac revascularization after CCta
Obstructive CAD was found on CCTA in 126 of 792 (15.9%) 
patients. All 126 patients were referred for CC. On CC, ob-
structive CAD was confirmed in 102 (81%) of these patients 
and all underwent revascularization. In 24 (19%) patients 
with obstructive CAD, CCTA diagnosis was not confirmed 
by the control CC.
Follow up: major adverse cardiac events (MaCe) after 
CCta
Obstructive CAD was excluded on CCTA in 666 patients, 
and they were subjected to 12-month clinical follow-up. 
During  the  follow-up  period,  the  following  MACE  were 
sought for: cardiac death, nonfatal myocardial infarction, 
unstable angina, and late revascularization that was not in-
dicated on CCTA.
A total of 651 of 666 (97.7%) patients were free of MACE 
during the entire follow-up period (Table 2), including all 
276 patients with no CAD on CCTA and 375 of 390 (96.2%) 
patients with non-obstructive CAD on CCTA. The difference 
between patients with no CAD on CCTA and patients with 
non-obstructive CAD on CCTA was significant (P < 0.001). 
Of patients in whom CCTA excluded obstructive CAD, all 
96 patients with low risk, 360 of 369 patients with inter-
mediate risk (97.6%), and 195 of 201 patients with high 
risk (97%) were free of MACE during the follow-up 
period (Table 2). The differences between the three risk 
groups in this respect were not significant (P = 0.26). A total 
of 15 patients with non-obstructive CAD on CCTA devel-
oped a MACE during the entire follow-up period; 9 had in-
termediate and 6 high risk (Table 3). An overall MACE rate 
of 2.3% during the first year after CCTA was recorded.
DisCussion
CCTA excluded obstructive CAD in 666 of 792 (84.1%) pa-
tients. During the 12-month clinical follow-up, 97.7% of these 
patients were free of MACE. All patients with no CAD and 
96.2% of patients with non-obstructive CAD on CCTA were 
free of MACE during the entire follow-up period, and the dif-
ference between these two groups was significant (P < 0.05). 
On CCTA, CC indication was revoked in 77.2% of previous-
ly scheduled patients and medical therapy was modified in 
37.5% of patients, in 94.9% of whom it was increased.
Several  previous  studies  demonstrated  a  low  incidence 
of  cardiac  events  for  patients  without  obstructive  CAD 
on CCTA (15-20). Most of these studies showed an event 
rate below 1% per year for severe cardiac events. However, 
except in the study by Hadamitzky et al, all other investi-
gations encompassed rather small or very selected pop-
ulations of patients (21). Furthermore, different studies in-
vestigated various adverse cardiac events.
In our population of 666 patients with obstructive CAD ex-
cluded on CCTA, an annual event rate of MACE was 2.2%. 
All MACE were related to the unstable angina and late 
revascularization (which was not indicated by CCTA). There 
taBLe 2. number of patients free of major adverse cardiac 
events according to the risk stratification
Morise pre-test risk (9) no CaD* non-obstructive CaD* total
Low   45   51   96
Intermediate 156 204 360
High   75 120 195
Total 276 375 651
*Coronary artery disease.
taBLe 3. Major adverse cardiac events during the follow-up 
period
Major adverse cardiac events
non-obstructive 
coronary artery disease
Cardiac death  0
Nonfatal myocardial infarction  0
Unstable angina  6
Late revascularization  9
Total 159 Jukić et al: Influence of coronary CT-angiography on patient management
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were no cases of nonfatal myocardial infarction or cardiac 
death. Among patients with no CAD on CCTA, there were 
no cases of MACE during the 12-month follow-up peri-
od. Significantly more MACE occurred among patients in 
whom CCTA revealed non-obstructive CAD. On the oth-
er hand, after CCTA excluded obstructive CAD, there was 
no difference in the number of MACE between the groups 
with different Morise pre-test risk stratification.
In a recent study on the diagnostic yield of CC on a sam-
ple of 398 978 patients, obstructive CAD was found in only 
37.6% of participants (22). In our study, due to CCTA, indi-
cation for CC was revoked in 77.2% of previously sched-
uled patients. Moreover, indication for CC was deemed un-
necessary in 72.6% of high-risk patients, and in even more 
patients (80.7%) with intermediate risk.
We are not aware of previous studies that examined the 
impact of CCTA on changes in medical therapy. In our pop-
ulation, 86% of patients had received some form of medical 
therapy for CAD before the CCTA was performed. Never-
theless, in 54.7% of patients in whom CAD was confirmed 
on CCTA, the therapy had to be increased to achieve OMT. 
The therapy was increased in significantly more patients 
with high risk than with low and intermediate risk.
Due to the specific situation in our country and the long 
waiting  lists  for  elective  CC,  we  included  patients  with 
somewhat higher risk than usually recommended (23) – 
34.1% had high risk and only 12.5% had low risk for CAD. 
Nevertheless, 97.7% of patients in whom CCTA excluded 
obstructive  CAD,  and  after  optimization  of  the  medical 
therapy, were free of MACE during the 12-month follow-
up period, regardless of the pre-test risk stratification.
A limitation of the study might be that it did not include 57 
patients with technically unsatisfactory CCTA, since the fur-
ther management was performed elsewhere. Also, for the 
same reason, this study did not include patients with ob-
structive CAD on CCTA that was not confirmed on control 
CC prior to revascularization due to organizational difficul-
ties. Although the period between CCTA and revasculariza-
tion in these patients did not exceed 4 weeks, this could 
have affected the overall results. Also, we did not determine 
the occurrence of adverse cardiac events other than MACE.
Our results indicate that CCTA can consistently exclude sig-
nificant CAD not only in patients with low and moderate, 
but also with high risk. CCTA can also replace CC in the ma-
jority of elective patients regardless of the risk stratification. 
In addition, they that CCTA can help reclassify risk and op-
timize medical therapy in patients with CAD. The potential 
role of CCTA in patients with high risk for CAD needs to be 
further explored, as well as a possible role of CCTA as a re-
placement for elective CC. Another area of future research 
may involve the analysis of how and why the findings of 
CCTA influence the choice of medical therapy for CAD.
Funding None.
ethical approval Received from the ethics committee of the Sunce Clinic, 
Zagreb, Croatia.
Declaration of authorship MJ contributed to the conception and design, 
analysis and interpretation of data; drafted the manuscript and revised it 
critically for important intellectual content; and gave the final approval of 
the version to be published. LP contributed to the conception and design of 
the study and acquisition of data; analysis and interpretation of data; draft-
ed the manuscript and revised it critically for important intellectual content; 
and gave the final approval of the version to be published. JCH contributed 
to the conception and design of the study, acquisition of data; analysis and 
interpretation of data; drafted the manuscript and revised it critically for im-
portant intellectual content; and gave the final approval of the version to be 
published. PM sorted the collected raw data, created the tables for further 
statistical interpretation, and wrote parts of the manuscript. DDB prepared 
the manuscript, interpreted findings and results, and revised the final ver-
sion of the manuscript. BB contributed to analysis of data, critical revision 
of data for important intellectual content, drafted the conclusion, and gave 
the final approval of the version to be published.
Competing interests All authors have completed the Unified Competing 
Interest  form  at  www.icmje.org/coi_disclosure.pdf  (available  on  request 
from the corresponding author) and declare: no support from any organi-
zation for the submitted work; no financial relationships with any organiza-
tions that might have an interest in the submitted work in the previous 3 
years; no other relationships or activities that could appear to have influ-
enced the submitted work.
references
1  Yusuf s, reddy s, ounpuu s, anand s. Global burden of 
cardiovascular diseases: part i: general considerations of the 
epidemiology transition, risk factors and impact of urbanization. 
Circulation. 2001;104:2746-53. Medline:11723030 doi:10.1161/
hc4601.099487
2  american Heart association. Heart diseases and stroke statistics-
2009. update. Dallas (tX): american Heart association; 2009.
3  the World Health organization. the global burden of disease. 
available from: http://www.who.int/healthinfo/global_burden_
disease/GBD_report_2004update_full.pdf. accessed: February 6, 
2012.
4  nieman K, Cademartiri F, Lemos Pa, raaijmarkers r, Pattynama 
PM, deFeyter PJ. reliable noninvasive coronary angiography 
with fast submilimeter multislice spiral computed tomography. 
Circulation. 2002;106:2051-4. Medline:12379572 doi:10.1161/01.
Cir.0000037222.58317.3D
5  Lin F, shaw LJ, Berman Ds, Callister tQ, Weinsaft JW, Wong FJ, et 
al. Multidetector computed tomography coronary artery plaque 
predictors of stress-induced myocardial ischemia by sPeCt. 
atherosclerosis. 2008;197:700-9. Medline:17720167 doi:10.1016/j.HEART DISEASES 10 Croat Med J. 2012;53:4-10
www.cmj.hr
atherosclerosis.2007.07.002
6  Lin FY, saba s, Weinsaft JW, Wong FJ, szulc M, Kligfeld P, et al. 
relation of plaque characteristics defined by coronary computed 
tomographic angiography to st-segment depression and 
impaired functional capacity during exercise treadmill testing 
in patients suspected of having coronary heart disease. am 
J Cardiol. 2009;103:50-8. Medline:19101229 doi:10.1016/j.
amjcard.2008.08.029
7  Halon Da, rubinshtein r, Gaspar t, Peled n, Lewis Bs. Current 
status and clinical applications of cardiac multidetector computed 
tomography. Cardiology. 2008;109:73-84. Medline:17664871
8  the task Force on Myocardial revascularization of the european 
society of Cardiology (esC) and the european association for 
Cardio-thoracic surgery.  (eaCts); european association for 
Percutaneous Cardiovascular interventions (eaPCi), Wijns W, 
Kolh P, Danchin n, Di Mario C, et al. Guidelines on myocardial 
revascularization. eur Heart J. 2010;31:2501-55. Medline:20802248
9  Morise aP, Jalisi F. evaluation of pretest and exercise test scores 
to assess all-cause mortality in unselected patients presenting 
for exercise testing with symptoms of suspected coronary artery 
disease. J am Coll Cardiol. 2003;42:842-50. Medline:12957430 
doi:10.1016/s0735-1097(03)00837-4
10  Wilson PW, D’agostino rB, Levy D, Belanger aM, silbershatz H, 
Kannel WB. Prediction of coronary heart disease using risk factor 
categories. Circulation. 1998;97:1837-47. Medline:9603539
11  Leschka s, scheffel H, Desbiolles L, Plass a, Gaemperli o, Valenta 
i, et al. image quality and reconstruction intervals of dual-source 
Ct coronary angiography: recommendations for eCG pulsing 
windowing. invest radiol. 2007;42:543-9. Medline:17620936 
doi:10.1097/rLi.0b013e31803b93cf
12  Hausleiter J, Meyer t, Hadamitzky M, Zankl M, Gerein P, Dörrler K, 
et al. non-invasive coronary computed tomographic angiography 
for patients with suspected coronary artery disease: the Coronary 
angiography by Computed tomography with the use of a 
submillimeter resolution (CaCtus) trial. eur Heart J. 2007;28:3034-
41. Medline:17540851 doi:10.1093/eurheartj/ehm150
13  austen WG, edwards Je, Frye rL, Gensini GG, Gott VL, Griffith Ls, 
et al. a reporting system on patients evaluated for coronary artery 
disease. report of the ad Hoc Committee for Grading of Coronary 
artery Disease, Council on Cardiovascular surgery, american Heart 
association. Circulation. 1975;51:5-40. Medline:1116248
14  Boden We, o’rourke ra, teo KK, Hartigan PM, Maron DJ, Kostuk 
WJ, et al; CouraGe trial research Group. optimal medical therapy 
with or without PCi for stable coronary disease. n engl J Med. 
2007;356:1503-16. Medline:17387127 doi:10.1056/neJMoa070829
15  Min JK, shaw LJ, Devereux rB, okin PM, Weinsaft JW, russo DJ, 
et al. Prognostic value of multidetector coronary computed 
tomographic angiography for prediction of all-cause mortality. J 
am Coll Cardiol. 2007;50:1161-70. Medline:17868808 doi:10.1016/j.
jacc.2007.03.067
16  Pundziute G, schuijf JD, Jukema JW, Boersma e, de roos a, 
van der Wall ee, et al. Prognostic value of multislice computed 
tomography coronary angiography in patients with known or 
suspected coronary artery disease. J am Coll Cardiol. 2007;49:62-
70. Medline:17207724 doi:10.1016/j.jacc.2006.07.070
17  Gilard M, Le Gal G, Cornily JC, Vinsonneau u, Joret C, Pennec PY, 
et al. Midterm prognosis of patients with suspected coronary 
artery disease and normal multislice computed tomographic 
findings: a prospective management outcome study. arch 
intern Med. 2007;167:1686-9. Medline:17698693 doi:10.1001/
archinte.167.15.1686
18  Gaemperli o, Valenta i, schepis t, Husmann L, scheffel H, Desbiolles 
L, et al. Coronary 64-slice Ct angiography predicts outcome in 
patients with known or suspected coronary artery disease. eur 
radiol. 2008;18:1162-73. Medline:18286291 doi:10.1007/s00330-
008-0871-7
19  Danciu sC, Herrera CJ, stecy PJ, Carell e, saltiel F, Hines JL. 
usefulness of multislice computed tomographic coronary 
angiography to identify patients with abnormal myocardial 
perfusion stress in whom diagnostic catheterization may be 
safely avoided. am J Cardiol. 2007;100:1605-8. Medline:18036355 
doi:10.1016/j.amjcard.2007.06.069
20  abdulla J, abildstrom sZ, Gotzsche o, Christensen e, Kober L. 
torpPedersen C. 64-multislice detector computed tomography 
coronary angiography as potential alternative to conventional 
coronary angiography: a systematic review and meta-analysis. 
eur Heart J. 2007;28:3042-50. Medline:17981829 doi:10.1093/
eurheartj/ehm466
21  Hadamitzky M, Freissmuth B, Meyer t, Hein F, Kastrati a, Martinoff 
s, et al. Prognostic value of coronary computed tomographic 
angiography for prediction of cardiac events in patients with 
suspected coronary artery disease. JaCC Cardiovasc imaging. 
2009;2:404-11. Medline:19580721 doi:10.1016/j.jcmg.2008.11.015
22  Patel Mr, Peterson eD, Dai D, Brennan JM, redberg rF, anderson 
HV, et al. Low diagnostic yield of elective coronary angiography. 
n engl J Med. 2010;362:886-95. Medline:20220183 doi:10.1056/
neJMoa0907272
23  Hendel rC, Patel Mr, Kramer CM, Poon M, Hendel rC, Carr 
JC, et al. aCCF/aCr/sCCt/sCMr/asnC/nasCi/sCai/sir 2006 
appropriateness criteria for cardiac computed tomography and 
cardiac magnetic resonance imaging: a report of the american 
College of Cardiology Foundation Quality strategic Directions 
Committee appropriateness Criteria Working Group, american 
College of radiology, society of Cardiovascular Computed 
tomography, society for Cardiovascular Magnetic resonance, 
american society of nuclear Cardiology, north american society 
for Cardiac imaging, society for Cardiovascular angiography 
and interventions, and society of interventional radiology. J am 
Coll Cardiol. 2006;48:1475-97. Medline:17010819 doi:10.1016/j.
jacc.2006.07.003